Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | PGR | P06401 | 6/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.52 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | SHBG | P04278 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trestolone Acetate SCHEMBL17302787 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL17302820 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL7779251 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL2787569 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL25863451 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL17302814 | 1.00 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| Trestolone Acetate SCHEMBL28108545 | 0.96 | AR (0.65) | ARMAPTLMNAPGRNR3C2 | |
| SCHEMBL24102452 | 0.92 | AR (0.70) | ARMAPTLMNAPGRNR3C2 | |
| SCHEMBL24102904 | 0.91 | AR (0.69) | ARMAPTLMNAPGRNR3C2 | |
| SCHEMBL24102896 | 0.91 | AR (0.69) | ARMAPTLMNAPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| EP-1608670-B1 | PROCESS FOR THE PRODUCTION OF TIBOLONE | RESOLUTION CHEMICALS LTD (GB) | 2013-09-11 | — | — | EP | disclosed |
| EP-2497776-A2 | Process for the production of tibolone | Resolution Chemicals Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| US-7884222-B2 | protecting the 17-hydroxy group and the 3-keto group of nandrolone, then halogenating, methylating, isomerizing, dehydrogenating, reducing, oxidizing, ethynylating and deprotecting to form 17 beta -hydroxy-7 alpha -methyl-19-nor-17 alpha -pregn-5(10)-ene-20-yne-3-one | RESOLUTION CHEMICALS LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7884222-B2 | protecting the 17-hydroxy group and the 3-keto group of nandrolone, then halogenating, methylating, isomerizing, dehydrogenating, reducing, oxidizing, ethynylating and deprotecting to form 17 beta -hydroxy-7 alpha -methyl-19-nor-17 alpha -pregn-5(10)-ene-20-yne-3-one | RESOLUTION CHEMICALS LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | AR 7/4885MAPT 4428/4885LMNA 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.